| [1] |
Zheng R, Zhang S, Zeng H, et al. Cancer incidence and mortality in China, 2016[J]. JNCC, 2022, 2(1): 1-9.
|
| [2] |
Wu W, He X, Andayani D, et al. Pattern of distant extrahepatic metastases in primary liver cancer: A SEER based study[J]. J Cancer, 2017, 8(12): 2312-2318.
|
| [3] |
Wu C, Ren X, Zhang Q. Incidence, risk factors, and prognosis in patients with primary hepatocellular carcinoma and lung metastasis: A population-based study[J]. Cancer Manag Res, 2019, 11: 2759-2768.
|
| [4] |
Hu Z, Li W, Huang P, et al. Therapeutic significance and indications of pulmonary metastasectomy for hepatocellular carcinoma following liver resection[J]. Int J Surg, 2017, 48: 23-31.
|
| [5] |
Lee HP, Yun JK, Jung HS, et al. Surgical outcomes of pulmonary metastasectomy in hepatocellular carcinoma patients according to approach method: thoracoscopic versus open approach[J]. World J Surg Oncol, 2021, 19(1): 33.
|
| [6] |
Mizuguchi S, Nishiyama N, Izumi N, et al. Clinical significance of multiple pulmonary metastasectomy for hepatocellular carcinoma[J]. World J Surg, 2016, 40(2): 380-387.
|
| [7] |
Kuo TM, Chang KM, Cheng TI, et al. Clinical factors predicting better survival outcome for pulmonary metastasectomy of hepatocellular carcinoma[J]. Liver Cancer, 2017, 6(4): 297-306.
|
| [8] |
叶欣，范卫君，王徽, 等. 热消融治疗原发性和转移性肺部肿瘤专家共识（2017年版）[J]. 中国肺癌杂志, 2017, 20(7): 433-445.
|
| [9] |
葛夕洪，刘祥，蔡金贞, 等. 肝癌肝移植术后肺寡转移瘤的微波消融治疗效果分析[J/CD]. 实用器官移植电子杂志, 2020, 8(5): 349-352.
|
| [10] |
Yuan Z, Liu B, Hu C, et al. Clinical outcomes of percutaneous thermal ablation for pulmonary metastases from hepatocellular carcinoma: A retrospective study[J]. Int J Hyperthermia, 2020, 37(1): 651-659.
|
| [11] |
Zuo T, Lin W, Liu F, et al. Artificial pneumothorax improves radiofrequency ablation of pulmonary metastases of hepatocellular carcinoma close to mediastinum[J]. BMC Cancer, 2021, 21(1): 505.
|
| [12] |
Hori A, Ohira R, Nakamura T, et al. Transarterial chemoembolization for pulmonary or mediastinal metastases from hepatocellular carcinoma[J]. Br J Radiol, 2020, 93(1110): 20190407.
|
| [13] |
李科，孔轶. 进口碘化油TACE联合洛铂治疗晚期肝癌肺转移的临床疗效观察[J]. 实用癌症杂志, 2018, 33(2): 244-246.
|
| [14] |
Wang Z, Kong QT, Li J, et al. Clinical outcomes of cyberknife stereotactic radiosurgery for lung metastases[J]. J Thorac Dis, 2015, 7(3): 407-412.
|
| [15] |
Zhang F, Wang J, Guo J, et al. Chinese Expert Consensus Workshop Report: Guideline for permanent iodine-125 seed implantation of primary and metastatic lung tumors[J]. Thorac Cancer, 2019, 10(2): 388-394.
|
| [16] |
Zhang L, Chen LH, Wang J, et al. CT-guided radioactive 125I seed implantation treatment of multiple pulmonary metastases of hepatocellular carcinoma[J]. Clin Radiol, 2014, 69(6): 624-629.
|
| [17] |
Soliman H, Ringash J, Jiang H, et al. Phase Ⅱ trial of palliative radiotherapy for hepatocellular carcinoma and liver metastases[J]. J Clin Oncol, 2013, 31(31): 3980-3986.
|
| [18] |
Pelizzaro F, Sammarco A, Dadduzio V, et al. Capecitabine in advanced hepatocellular carcinoma: A multicenter experience[J]. Dig Liver Dis, 2019, 51(12): 1713-1719.
|
| [19] |
Qin S, Bai Y, Lim HY, et al. Randomized, multicenter, open-label study of oxaliplatin plus fluorouracil/leucovorin versus doxorubicin as palliative chemotherapy in patients with advanced hepatocellular carcinoma from Asia[J]. J Clin Oncol, 2013, 31(28): 3501-3508.
|
| [20] |
Hasegawa H, Kawakubo E, Kitagawa D, et al. Combined modality therapy for giant hepatocellular carcinoma and multiple lung metastases-a case study[J]. Gan To Kagaku Ryoho, 2020, 47(13): 2251-2253.
|
| [21] |
Shi J, Sun J, Liu C, et al. All-trans-retinoic acid (ATRA) plus oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX) versus FOLFOX alone as palliative chemotherapy in patients with advanced hepatocellular carcinoma and extrahepatic metastasis: study protocol for a randomized controlled trial[J]. Trials, 2019, 20(1): 245.
|
| [22] |
Mao X, Tey SK, Yeung C, et al. Nidogen 1-enriched extracellular vesicles facilitate extrahepatic metastasis of liver cancer by activating pulmonary fibroblasts to secrete tumor necrosis factor receptor 1[J]. Adv Sci(Weinh), 2020, 7(21): 2002157.
|
| [23] |
Yoshida M, Yamashita T, Okada H, et al. Sorafenib suppresses extrahepatic metastasis de novo in hepatocellular carcinoma through inhibition of mesenchymal cancer stem cells characterized by the expression of CD90[J]. Sci Rep, 2017, 7(1): 11292.
|
| [24] |
冯跃，郑家平，邵国良. 索拉非尼治疗肝细胞癌肺转移39例预后分析[J]. 肿瘤学杂志, 2018, 24(10): 987-991.
|
| [25] |
Yang T, Lu JH, Lin C, et al. Concomitant lung metastasis in patients with advanced hepatocellular carcinoma[J]. World J Gastroenterol, 2012, 18(20): 2533-2539.
|
| [26] |
Chen J, Lu S, Zhang Y, et al. Sorafenib monotherapy versus sorafenib combined with regional therapies for hepatocellular carcinoma patients with pulmonary oligometastases: A propensity score-matched analysis[J]. J Cancer, 2018, 9(10): 1745-1753.
|
| [27] |
Li ZJ, Dai HQ, Huang XW, et al. Artesunate synergizes with sorafenib to induce ferroptosis in hepatocellular carcinoma[J]. Acta Pharmacol Sin, 2021, 42(2): 301-310.
|
| [28] |
Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial[J]. Lancet, 2018, 391(10126): 1163-1173.
|
| [29] |
Lee MJ, Chang SW, Kim JH, et al. Real-world systemic sequential therapy with sorafenib and regorafenib for advanced hepatocellular carcinoma: A multicenter retrospective study in Korea[J]. Invest New Drugs, 2021, 39(1): 260-268.
|
| [30] |
Du X, Chen D, Lin Z, et al. Efficacy of apatinib in advanced hepatocellular carcinoma with lung metastasis: A retrospective, multicenter study[J]. J BUON, 2019, 24(5): 1956-1963.
|
| [31] |
Zhu AX, Kang YK, Yen CJ, et al. Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): A randomised, double-blind, placebo-controlled, phase 3 trial[J]. Lancet Oncol, 2019, 20(2): 282-296.
|
| [32] |
El-Khoueiry AB, Sangro B, Yau T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): An open-label, non-comparative, phase 1/2 dose escalation and expansion trial[J]. Lancet, 2017, 389(10088): 2492-2502.
|
| [33] |
Kudo M, Matilla A, Santoro A, et al. CheckMate 040 cohort 5: A phase Ⅰ/Ⅱ study of nivolumab in patients with advanced hepatocellular carcinoma and Child-Pugh B cirrhosis[J]. J Hepatol, 2021, 75(3): 600-609.
|
| [34] |
Yau T, Park JW, Finn RS, et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): A randomised, multicentre, open-label, phase 3 trial[J]. Lancet Oncol, 2022, 23(1): 77-90.
|
| [35] |
Kim CG, Kim C, Yoon SE, et al. Hyperprogressive disease during PD-1 blockade in patients with advanced hepatocellular carcinoma[J]. J Hepatol, 2021, 74(2): 350-359.
|
| [36] |
Yau T, Kang YK, Kim TY, et al. Efficacy and safety of nivolumab plus ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib: the CheckMate 040 randomized clinical trial[J]. JAMA Oncol, 2020, 6(11): e204564.
|
| [37] |
Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma[J]. N Engl J Med, 2020, 382(20): 1894-1905.
|
| [38] |
Ren Z, Xu J, Bai Y, et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): A randomised, open-label, phase 2-3 study[J]. Lancet Oncol, 2021, 22(7): 977-990.
|
| [39] |
Xu J, Shen J, Gu S, et al. Camrelizumab in combination with apatinib in patients with advanced hepatocellular carcinoma (RESCUE): A nonrandomized, open-label, phase Ⅱ trial[J]. Clin Cancer Res, 2021, 27(4): 1003-1011.
|